Hillstar Bio, a Boston, MA-based biotechnology company focused on developing immunology therapies for autoimmune diseases, raised $67M in Series A funding.
Backers included Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience.
The company intends to use the funds to further enhance its lead program, which specifically targets TRBV9+ T cells, into clinical trials in 2026, and the expansion of its portfolio.
Led by CEO Robert Mabry, Hillstar Bio is a biotechnology company that selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief and immune reset for patients with autoimmune conditions. Its approach addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression.
Hillstar Bio’s Executive Team include:
- Robert Mabry, Ph.D., Chief Executive Officer, previously Chief Scientific Officer at Orna Therapeutics and Global Head of Biologics at Takeda
- Mitchell Keegan, Ph.D., Chief Development Officer, previously SVP of Clinical Development at Boston Pharmaceuticals and VP of Clinical Development at Verastem Oncology
- Lauren Mifflin, Ph.D., MBA, Chief Operating Officer, Principal of Company Creation at Frazier Life Sciences, previously on the founding teams of multiple venture-backed biotechs, including Ypsilon Therapeutics, Nido Biosciences, and Entrada Therapeutics.
The Board of Directors includes:
- Luc Dochez, Pharm.D., MBA, Executive Chair, Managing Partner, Droia Ventures
- Dan Estes, Ph.D., General Partner, Frazier Life Sciences
- Kenneth Harrison, Ph.D., Senior Partner, Novo Holdings A/S
- Piers Ingram, Ph.D., MBA, Chief Executive Officer, Hummingbird Bioscience
- Robert Mabry, Ph.D., Chief Executive Officer, Hillstar Bio
- Matthias Van Woensel, Ph.D., Partner, Droia Ventures
FinSMEs
25/03/2025